216 related articles for article (PubMed ID: 26503273)
1. Antileishmanial Activity of Compounds Derived from the Medicines for Malaria Venture Open Access Box Against Intracellular Leishmania major Amastigotes.
Khraiwesh M; Leed S; Roncal N; Johnson J; Sciotti R; Smith P; Read L; Paris R; Hudson T; Hickman M; Grogl M
Am J Trop Med Hyg; 2016 Feb; 94(2):340-347. PubMed ID: 26503273
[TBL] [Abstract][Full Text] [Related]
2.
Tadele M; Abay SM; Makonnen E; Hailu A
Drug Des Devel Ther; 2020; 14():1307-1317. PubMed ID: 32280200
[TBL] [Abstract][Full Text] [Related]
3. In vitro growth inhibitory activity of Medicines for Malaria Venture pathogen box compounds against Leishmania aethiopica.
Tadele M; Abay SM; Asaga P; Makonnen E; Hailu A
BMC Pharmacol Toxicol; 2021 Nov; 22(1):71. PubMed ID: 34784983
[TBL] [Abstract][Full Text] [Related]
4. In vitro antileishmanial activity of resveratrol and its hydroxylated analogues against Leishmania major promastigotes and amastigotes.
Kedzierski L; Curtis JM; Kaminska M; Jodynis-Liebert J; Murias M
Parasitol Res; 2007 Dec; 102(1):91-7. PubMed ID: 17763870
[TBL] [Abstract][Full Text] [Related]
5. Unveiling six potent and highly selective antileishmanial agents via the open source compound collection 'Pathogen Box' against antimony-sensitive and -resistant Leishmania braziliensis.
Souza Silva JA; Tunes LG; Coimbra RS; Ascher DB; Pires DEV; Monte-Neto RL
Biomed Pharmacother; 2021 Jan; 133():111049. PubMed ID: 33378956
[TBL] [Abstract][Full Text] [Related]
6. Development of a target-free high-throughput screening platform for the discovery of antileishmanial compounds.
Corman HN; Shoue DA; Norris-Mullins B; Melancon BJ; Morales MA; McDowell MA
Int J Antimicrob Agents; 2019 Oct; 54(4):496-501. PubMed ID: 31323307
[TBL] [Abstract][Full Text] [Related]
7. Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.
Borborema SE; Schwendener RA; Osso JA; de Andrade HF; do Nascimento N
Int J Antimicrob Agents; 2011 Oct; 38(4):341-7. PubMed ID: 21783345
[TBL] [Abstract][Full Text] [Related]
8. In vitro antileishmanial activity of novel azoles (3-imidazolylflavanones) against promastigote and amastigote stages of Leishmania major.
Shokri A; Emami S; Fakhar M; Teshnizi SH; Keighobadi M
Acta Trop; 2017 Mar; 167():73-78. PubMed ID: 28017860
[TBL] [Abstract][Full Text] [Related]
9. Development of a New Antileishmanial Aziridine-2,3-Dicarboxylate-Based Inhibitor with High Selectivity for Parasite Cysteine Proteases.
Schad C; Baum U; Frank B; Dietzel U; Mattern F; Gomes C; Ponte-Sucre A; Moll H; Schurigt U; Schirmeister T
Antimicrob Agents Chemother; 2016 Feb; 60(2):797-805. PubMed ID: 26596939
[TBL] [Abstract][Full Text] [Related]
10. In-Vitro Evaluation of 52 Commercially-Available Essential Oils Against
Monzote L; Herrera I; Satyal P; Setzer WN
Molecules; 2019 Mar; 24(7):. PubMed ID: 30934998
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Infectivity Assessment by Drug Susceptibility Comparison of Recombinant Leishmania major Expressing Enhanced Green Fluorescent Protein or EGFP-Luciferase Fused Genes with Wild-Type Parasite.
Sadeghi S; Seyed N; Etemadzadeh MH; Abediankenari S; Rafati S; Taheri T
Korean J Parasitol; 2015 Aug; 53(4):385-94. PubMed ID: 26323836
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of Leishmania GDP-mannose pyrophosphorylase identified by high-throughput screening of small-molecule chemical library.
Lackovic K; Parisot JP; Sleebs N; Baell JB; Debien L; Watson KG; Curtis JM; Handman E; Street IP; Kedzierski L
Antimicrob Agents Chemother; 2010 May; 54(5):1712-9. PubMed ID: 20160053
[TBL] [Abstract][Full Text] [Related]
13. Use of Optical Imaging Technology in the Validation of a New, Rapid, Cost-Effective Drug Screen as Part of a Tiered
Caridha D; Parriot S; Hudson TH; Lang T; Ngundam F; Leed S; Sena J; Harris M; O'Neil M; Sciotti R; Read L; Lecoeur H; Hickman M; Grogl M
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137819
[TBL] [Abstract][Full Text] [Related]
14. Development of Thiophene Compounds as Potent Chemotherapies for the Treatment of Cutaneous Leishmaniasis Caused by
Rodriguez F; Iniguez E; Pena Contreras G; Ahmed H; Costa TEMM; Skouta R; Maldonado RA
Molecules; 2018 Jul; 23(7):. PubMed ID: 29973498
[No Abstract] [Full Text] [Related]
15. An
Eskandari EG; Doudi M; Abedi S
J Vector Borne Dis; 2016; 53(4):362-369. PubMed ID: 28035114
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of ferrocenylquinoline as a potential antileishmanial agent.
Yousuf M; Mukherjee D; Pal A; Dey S; Mandal S; Pal C; Adhikari S
ChemMedChem; 2015 Mar; 10(3):546-54. PubMed ID: 25619822
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of Thiocarbohydrazones and Evaluation of their in vitro Antileishmanial Activity.
Muhammad MT; Ghouri N; Khan KM; Arshia ; Choudhary MI; Perveen S
Med Chem; 2018; 14(7):725-732. PubMed ID: 29332596
[TBL] [Abstract][Full Text] [Related]
18. Nano-based antileishmanial agents: a toxicological study on nanoparticles for future treatment of cutaneous leishmaniasis.
Jebali A; Kazemi B
Toxicol In Vitro; 2013 Sep; 27(6):1896-904. PubMed ID: 23806227
[TBL] [Abstract][Full Text] [Related]
19. In Vivo Bioluminescent Monitoring of Parasites in BALB/c Mouse Models of Cutaneous Leishmaniasis Drug Discovery.
Caridha D; Leed S; Cawlfield A
Methods Mol Biol; 2020; 2081():81-106. PubMed ID: 31721120
[TBL] [Abstract][Full Text] [Related]
20. Repurposing azole antifungals into antileishmanials: Novel 3-triazolylflavanones with promising in vitro antileishmanial activity against Leishmania major.
Keighobadi M; Emami S; Fakhar M; Shokri A; Mirzaei H; Hosseini Teshnizi S
Parasitol Int; 2019 Apr; 69():103-109. PubMed ID: 30582997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
